TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Immunogenicity of 3-dose regimen of Rotavac
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensorial and motor block duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bone or joint pains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of adverse device effects (ADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious adverse device effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Avoidance of hypoglycemia and hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety outcomes and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative and postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Additional narcotic use
Endpoint domain: Adverse events/effects
Primary endpoint: C-reactive protein blood values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Metamorphopsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of central scotoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central fovea thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of complement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in metabolic control (tyrosine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in metabolic control (phenylalanine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident invasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Urine phosphate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in Minutes That Tq Remained Inflated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra Thoracic Gas Volume (ITGV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Effects of H1N1 vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ΔE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penn Shoulder Score (PENN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-op Pain measured using a Numeric Scale; 0-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year disease-specific survival (5y-DSS)
Endpoint domain: Mortality/survival
Primary endpoint: Margin detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of subjects achieving complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supplemental oxygen at 6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of bacterial DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of a characteristic microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eradication of bacterial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cumulative Amount of Morphine Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain by CMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of ECT-001-CB
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Use Patch After Abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in ICIQ-UI SF score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of women with Treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in systemic laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cervicovaginal mucosa by visual inspection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Emesis and Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Adipokines/cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in the First Second (FEV1) % Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC of Interferon (IFN) Beta-1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of Neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event (AE) and Serious Adverse Event (SAE) Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Pizza Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of Subjects in Study Assessments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recruitment of Subjects Into Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subject Attendance to Program Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ability to identify sentinel lymph node (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ability to identify parathyroid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in masseter muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change From Baseline in IgM Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in IgG1 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Interferon Gamma Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mobility of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of falls and near falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of IUD Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of new squamous cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Lesions That Received Invasive Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Lesions Receiving Invasive Treatment That Extended Into Dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically Relevant Thrombocytopenic Events (CRTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Hip Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption of Wound Exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Positive rate of HCMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative decrease in NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: State and Trait levels of Hopelessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endothelial Dysfunction (Arterial Stiffness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Point prevalence of chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Blood Markers of Muscle Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in subjective recovery scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fecal bifidobacteria counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tau Deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence Rate of All Seizures Through 0 to 3 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Febrile Seizures Through 0 to 3 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Urticaria and Angioedema Through 0 to 3 Days After Dose 1
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteremia assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Transfusion Independence Rate (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Illumination Pupil Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Artery resistance index of ophthalmic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Perioperative Plasma 15 f2t isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who have successfully eradicated HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: All-cause mortality at study day 28
Endpoint domain: Mortality/survival
Primary endpoint: Number of Ventilator Free Days until day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Major FM syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Dihydroergotamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-48) of Dihydroergotamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual Height Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glittre ADL-Test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: London Chest Activity of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants with Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Diaphragm Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Brunnstrom's motor recovery stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Rehabilitation Assessment of Movement scale; STREAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke-Specific Quality of Life scale; SS-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stroke Impact Scale; SIS 3.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gut microbiota structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm blood flow (FBF) response to Acetylcholine (ACh)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LUS Scores at T5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient/carer questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: complications during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new onset atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of complete AVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation coefficient between semi-quantitative CT score and FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline Pain Intensity at Three Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Headache Intensity at Three Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Range of Motion of the Neck at Three Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Depression Status at Three Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Adverse events after pCAR-19B infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Obtain the maximum tolerated dose of pCAR-19B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hopkins Verbal Learning test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Simple & Choice Reaction time task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wechsler Adult Intelligence scale (WAIS IV) Digit Span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Posner's Covert Attention test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinician's Assessment of Fluctuations scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of Respiratory Support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sum of Pain Intensity Difference on Weight Bearing Over 3 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Ankle Pain Intensity Difference on Weight Bearing Over 24 Hours After Dose 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale - 28
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity for nodule characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in tissue health variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of major device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Cost Per Participant of Consultations With Health Care Providers (HCPs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Cost Per Participant of Elective Surgical Procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Cost Per Participant Due to Non-elective/Emergency Inpatient Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Cost Per Participant for Admissions for Day Case Surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Cost Per Participant for All Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Cost Per Participant of Accident and Emergency (A&E) Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Viremia and antigenemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Number of Nocturic Episodes/Night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent of Participants With at Least 50% Decrease in Mean Nocturic Episodes Per Night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Chronic prostatitis symptom index total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Association with vulvodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement on a 7-point ordinal scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of cardiac valve calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rosenbek's Penetration-Aspiration Score (PAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breastfeeding self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mother-infant attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Device expulsion
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy in preventing pregnancy
Endpoint domain: Physiological/clinical
Primary endpoint: Device malposition
Endpoint domain: Adverse events/effects
Primary endpoint: α-diversity in saliva samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the liraglutide plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed liraglutide plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in incidence and severity of application site adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in incidence and severity of all AEs and their relationship to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in safety laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in calcium homeostasis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Determination of plasma concentrations of Pefcalcitol and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in apparent diffusion coefficient (ADC) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin Score by mRSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Western Aphasia Battery (WAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Communicative Activity Log (CAL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Stroke Aphasia Depression Questionnaire (SADQ-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stroke and Aphasia Quality of Life Scale 39 (SAQOL-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Orbital Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with drug related first-cycle dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (CR+R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Undetectable Plasma Viral Load (VL) Values (<50 Copies/mL) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exercise Participation Rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abdominal muscles peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Abdominal muscles thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of postoperative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccination status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Who Develop Diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Parkinson's Disease Quality of Life Questionnaire (PDQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AMC Linear Disability Score (ALDS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Y-BOCS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Panic and Agoraphobia Scale (PAS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percent change in inflammatory acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes